Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128886 | 0.92 | EPHX2 (0.46) | EPHX2CHRM2CHRM1USP2SMN1; SMN2 | |
| SCHEMBL20128889 | 0.89 | CHRM2 (0.42) | EPHX2CHRM2CHRM1USP2SMN1; SMN2 | |
| SCHEMBL20233741 | 0.89 | CHRM2 (0.42) | EPHX2CHRM2CHRM1USP2SMN1; SMN2 | |
| SCHEMBL27097883 | 0.88 | EPHX2 (0.43) | EPHX2CHRM2CHRM1HPGD | |
| SCHEMBL20572790 | 0.85 | EPHX2 (0.41) | EPHX2CHRM2CHRM1USP2SMN1; SMN2 | |
| SCHEMBL20572791 | 0.85 | EPHX2 (0.41) | EPHX2CHRM2CHRM1USP2SMN1; SMN2 | |
| SCHEMBL23122873 | 0.82 | DDB1 (0.43) | CHRM2CHRM1USP2SMN1; SMN2CHRM4 | |
| SCHEMBL20128902 | 0.82 | EPHX2 (0.46) | EPHX2CHRM2CHRM1USP2SMN1; SMN2 | |
| SCHEMBL20120245 | 0.82 | EPHX2 (0.46) | EPHX2CHRM2CHRM1USP2SMN1; SMN2 | |
| SCHEMBL20120247 | 0.82 | EPHX2 (0.46) | EPHX2CHRM2CHRM1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | EPHX2 3301/4885CHRM2 4475/4885CHRM1 4354/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | EPHX2 2978/4885CHRM2 4590/4885CHRM1 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.